Tesamorelin: Turning Up the Body's Own Growth-Hormone Pulse

The short version

Tesamorelin is a synthetic version of a hormone the brain naturally makes, called growth hormone-releasing hormone. Rather than supplying growth hormone directly, the way an injection of growth hormone itself would, tesamorelin signals the pituitary gland to release more of its own — amplifying a rhythm the body already runs rather than overriding it.

It is FDA-approved for exactly one purpose: reducing excess abdominal, or visceral, fat in people with HIV-associated lipodystrophy, a fat-redistribution condition linked to antiretroviral treatment. In a pooled analysis of five randomized trials, it reduced visceral fat by an average of roughly 28 square centimeters and increased lean body mass by about 1.4 kilograms, without serious adverse events ^[18]. Its effect is not permanent — visceral fat drifts back once dosing stops ^[22] — and it has not been approved for general fat loss or any use outside that one HIV-related indication. Nothing on this page is a recommended dose or a plan for weight loss in a person without that diagnosis.

What it is

Tesamorelin acetate is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone, GHRH(1-44)-NH2, with a trans-3-hexenoic acid group attached to its N-terminus. That modification is what makes it a viable drug rather than a fleeting signal: it blocks cleavage by the enzyme dipeptidyl peptidase-IV, extending its plasma stability well beyond native GHRH's few-minute lifespan. The free base has the empirical formula C221H366N72O67S; it is supplied clinically as the acetate salt.

How it works

Tesamorelin binds the growth hormone-releasing hormone receptor on somatotroph cells in the anterior pituitary, activating a signaling cascade that stimulates synthesis and pulsatile release of the body's own growth hormone. That endogenous growth hormone then drives hepatic production of insulin-like growth factor-1, or IGF-1; together, growth hormone and IGF-1 promote lipolysis with a preference for visceral, deep-abdominal, fat over subcutaneous fat. In healthy men, two weeks of tesamorelin measurably raised both signals — overnight growth hormone increased and IGF-1 rose sharply — without a significant effect on fasting glucose or insulin-stimulated glucose uptake, at least over that short window ^[21].

Because tesamorelin works by amplifying the body's own pulsatile growth-hormone rhythm rather than delivering growth hormone directly, its metabolic profile differs somewhat from recombinant growth hormone therapy, particularly around glucose handling — a distinction the trial data below explore directly.

What the research shows

Pooled meta-analysis, the largest evidence base for this compound. A 2026 meta-analysis pooling five randomized controlled trials in HIV-associated lipodystrophy found tesamorelin reduced visceral adipose tissue by a mean difference of -27.71 cm2, 95% CI -38.37 to -17.06, P<0.001, trunk fat by -1.18 kg, and hepatic fat fraction by -4.28%, while increasing lean body mass by +1.42 kg — all statistically significant, with no serious adverse events reported across the pooled trials ^[18].

Pivotal randomized trial. In a 6-month randomized trial of 50 antiretroviral-treated adults with HIV, 28 on tesamorelin and 22 on placebo, tesamorelin 2 mg/day produced a treatment effect of -42 cm2 in visceral fat, P=0.005, and reduced hepatic lipid content by a net -2.9%, P=0.003 ^[20].

Long-term program, 52 weeks. Across a combined program of 273 tesamorelin recipients versus 137 on placebo, visceral-fat reduction was sustained at -18% relative to baseline through 52 weeks, P<0.001; visceral fat began reaccumulating once tesamorelin was stopped, and glucose parameters over the full 52 weeks did not change to a clinically significant degree ^[22].

Mechanism confirmation in healthy men. In 13 healthy men given tesamorelin 2 mg/day for two weeks, mean overnight growth hormone rose by 0.5 microgram/L, P=0.004, and IGF-1 rose by 181 microgram/L, P<0.0001, while neither fasting glucose, P=0.93, nor insulin-stimulated glucose uptake, P=0.61, changed significantly ^[21].

Regulatory and liver-safety record. Tesamorelin was approved in the United States in 2010 for HIV-associated lipodystrophy; the NIH's LiverTox monograph assigns it a likelihood score of E, an unlikely cause of clinically apparent liver injury, noting no attributable liver-injury cases and no new serum-enzyme elevations across its trial record ^[19].

Reported effects, cautions & safety

Tesamorelin does not have the large, informal research-use community that the incretin peptides on this desk do, and this compound's source material does not include community-report data to draw on — so unlike the other three pages on this desk, there is no anecdotal-effects section to render here; what follows is drawn entirely from the published clinical and regulatory record.

Cited cautions: tesamorelin's FDA approval is narrow, limited to HIV-associated lipodystrophy, and every other proposed use — general visceral-fat reduction, anti-aging, cognitive support, non-HIV fatty liver disease — is off-label and investigational, resting on a pivotal trial base conducted specifically in antiretroviral-treated HIV-positive adults ^[19][20][22]. Its central practical limitation is that the benefit does not persist: visceral fat measurably reaccumulates once dosing stops, meaning any effect is contingent on continued treatment ^[22]. Because the mechanism works by raising endogenous IGF-1, a growth factor, through amplified growth-hormone pulsatility, and IGF-1 rose sharply even after just two weeks of dosing in healthy men ^[21], active malignancy is a labeled contraindication; the trial record through 52 weeks shows no excess malignancy signal, but long-term oncologic surveillance data beyond that window are limited ^[21][22]. Glucose parameters have not shown a clinically significant change across the pooled 52-week program ^[22], though clinicians monitor patients with pre-existing dysglycemia as a precaution given the drug's connection to the growth-hormone/IGF-1 axis. A small number of studies have explored cognitive effects, with mixed results to date — this remains a preliminary line of inquiry rather than an established finding. As a GHRH analogue, tesamorelin is prohibited in sport under the WADA Prohibited List, category S2, in- and out-of-competition. Research-grade tesamorelin sold outside the approved pharmaceutical product lacks the purity and potency oversight of the regulated drug.

Where it fits in metabolic research

Tesamorelin is the odd one out on this desk mechanistically — it doesn't touch the GLP-1/GIP/glucagon incretin axis that retatrutide and semaglutide work through at all. It raises the body's own growth-hormone signal instead, and its approved use is narrower than either of theirs: one specific fat-redistribution condition in one specific patient population, rather than general obesity or diabetes. Its evidence base, while smaller than semaglutide's, is genuinely solid within that narrow lane — a 2026 five-trial meta-analysis ^[18] backing up a pivotal randomized trial ^[20] and a year-long safety program ^[22]. Placed next to AOD-9604, another growth-hormone-axis compound with a much thinner human efficacy record, tesamorelin is the reminder that this receptor family can produce a real, approved, replicated clinical benefit — just not the kind of broad metabolic rewrite the incretin compounds are chasing. See the comparison page for all four together.